KOSDAQIT & Software223250

DreamCIS

₩3,020▲ 1.68%2026-11-18 close
Market Cap
₩74.3B
Turnover
₩100M
Volume
50K
Shares out.
24.6M
PER
—
PBR
1.3×
EPS
-₩632
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Growing CRO Revenue, Profitability Still the Test

DreamCIS revenue rose three straight years from 2023 through 2025, and media reported record cumulative revenue for the first three quarters of 2026, yet attributable net losses have run for four consecutive quarters since Q4 2025, leaving profitability as the central test.

  1. 1

    Revenue grew from KRW 38.9 billion in 2022 to KRW 66.6 billion in 2025, the largest year in the 2022–2025 span.

  2. 2

    Operating margin fell from 15.0% in 2022 to 3.3% in 2023 and recovered to 7.9% in 2025, still below the 2022 level.

  3. 3

    The company has posted losses for four consecutive quarters from Q4 2025 through Q3 2026, with attributable net losses totaling KRW 15.2 billion over that span.

  4. 4

    Media reports put the backlog at approximately KRW 238.5 billion at the end of Q3 2026, and how quickly that backlog converts into revenue is the next thing to watch.

  5. 5

    The company says inquiries from Chinese biotech firms about Korean trials are growing quickly, and how much of that demand shows up in results remains the question.

02

Business structure

DreamCIS is a clinical research organization (CRO) that runs clinical trials for pharmaceutical and biotech clients, with post-marketing surveillance (PMS) and trial services at the core.

Media coverage presents the company as the top domestic CRO, and reports say research services such as rPMS and non-interventional studies (NIS) drove recent top-line growth. Media reports tied expanded collaboration with multinational pharmaceutical firms to growth in trial awards alongside PMS in 2024.

DreamCIS was acquired in 2015 by Tigermed, a China-based CRO group, and it draws on Tigermed's network across 52 countries. Hong Kong-based Tigermed holds 59.57% as the largest shareholder, so the China link forms a structural pillar of the business.

The company offers clients an integrated one-stop drug development platform spanning its subsidiaries, affiliates and Tigermed. Its subsidiary Curi Bio, a U.S. organoid company in which DreamCIS acquired a stake, is positioned as a gateway into animal-replacement testing.

According to reports, the company filed as trial sponsor for a Phase 3 clinical trial plan for obesity candidate BGM0504 in Korea. CRO operations remain the core revenue base, and the company itself has cited subsidiary expansion costs as a drag on consolidated profit. The CEO has set a goal of entering the global top 10 CROs rather than remaining the top domestic player.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩16.5B₩2.8B16.9%
2025Q4₩19.3B-₩400M−2.0%
2026Q1₩17.4B₩500M3.1%
2026Q2₩20B₩2.3B11.3%
2026Q3₩17.5B₩500M2.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩38.9B₩5.8B₩4.4B15.0%9.0%54.6%
2023₩47.8B₩1.6B₩3.7B3.3%6.8%55.7%
2024₩58.7B₩5.1B₩5.3B8.6%7.8%54.8%
2025₩66.6B₩5.2B₩7.1B7.9%9.3%88.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 38.9 billion in 2022 to KRW 47.8 billion in 2023 (up 23.1% year on year), KRW 58.7 billion in 2024 (up 22.6%) and KRW 66.6 billion in 2025 (up 13.6%), growing three straight years from 2023 through 2025, with 2025 the largest year in the 2022–2025 span.

Operating profit bottomed at KRW 1.59 billion in 2023 (down 72.7%), then rose to KRW 5.06 billion in 2024 (up 218.5%) and KRW 5.24 billion in 2025 (up 3.6%), growing two consecutive years but still below KRW 5.82 billion in 2022.

Operating margin fell from 15.0% in 2022 to 3.3% in 2023 and recovered to 8.6% in 2024 and 7.9% in 2025, so margins did not return to the 2022 level even as revenue expanded.

Attributable net income moved from KRW 4.41 billion in 2022 to KRW 3.74 billion in 2023 (down 15.1%), then KRW 5.28 billion in 2024 (up 41.2%) and KRW 7.13 billion in 2025 (up 35.0%), growing two consecutive years after 2023.

The company attributed 2025 net income growth to stronger sales activity, better profitability and operating efficiency, and a rise in the value of investee companies; net income including non-controlling interests was KRW 7.51 billion in 2025.

The debt-to-equity ratio jumped to 88.6% in 2025 from 54.8% in 2024, and the company said financing costs, including interest on convertible bonds issued last year, weighed on consolidated results. Operating cash flow swung from -KRW 85.19 million in 2024 to KRW 14.1 billion in 2025.

By quarter, Q3 2025 posted operating profit of KRW 2.79 billion and attributable net income of KRW 13.4 billion, before Q4 2025 turned to an operating loss of KRW 388 million and an attributable net loss of KRW 8.6 billion.

Operating profit returned to the black in Q1 2026 at KRW 539 million and rose to KRW 2.27 billion in Q2 2026, but attributable net losses continued at KRW 116 million in Q1 and KRW 4.35 billion in Q2.

Q3 2026 revenue of KRW 17.5 billion rose 6.1% year on year, yet operating profit fell to KRW 469 million (down 83.2%) and the attributable net loss was KRW 2.18 billion, which marks four consecutive quarters of losses with attributable net losses totaling KRW 15.2 billion over the last four quarters.

For Q1 2026, the company attributed consolidated pressure to temporary costs from subsidiary expansion, convertible bond interest and valuation losses tied to a decline in the share price of an investee; separately, standalone revenue of KRW 12.8 billion (up 23.2%) and operating profit of KRW 1.3 billion (up 45.1%) reportedly grew.

05

Industry analysis

Demand for CRO services comes from pharmaceutical and biotech companies outsourcing clinical trials, and DreamCIS points to demand from Chinese biotech firms for Korean trials as a new growth driver.

In June 2026 the company said inquiries about Korean IND filings and global trial consulting from Chinese biotechs were rising quickly. The company describes this demand as coming from Chinese biotechs seeking Korean clinical data before signing licensing deals with global big pharma.

The company says it is virtually the only domestic CRO with a direct collaboration channel with Tigermed. A brokerage report cited in a June 2026 media article projected that bridge-trial demand from China-listed biotechs would meaningfully contribute to growth from 2026.

Rapid growth in China's clinical trial market was cited as background for that expectation. In May 2026 the company held a Korea-China clinical trial symposium in Hangzhou, which it said drew attention from Chinese biotech firms.

Industry commentary frames this trend as likely to ignite growth momentum in the core CRO business. Trial delays or client schedule changes can push back the timing of revenue recognition even when backlog is large.

Media coverage presents the company as the top domestic clinical CRO, and it cites expanded collaboration with multinational pharmaceutical firms as a source of competitiveness.

06

Outlook

The company says it will pursue continued growth in its core CRO business alongside new business ventures, aiming for sustained growth and better profitability. Backlog stood at approximately KRW 238.5 billion at the end of Q3 2026, a gauge of how much future revenue is already contracted.

Media coverage cited that backlog as the basis for expecting continued growth. According to the company, standalone core-business results improved in Q1 2026, while the consolidated profit decline reflected costs from subsidiary expansion.

Phase 3 clinical trial plan for obesity candidate BGM0504 was approved in Korea, and follow-on trials and approval efforts are proceeding. The CEO said the company will focus on organoid technology as its future growth engine.

In May 2026, the CEO and two senior executives disclosed open-market purchases of company shares. Three points remain to be confirmed: whether operating margin climbs back above the 7.9% level of 2025, whether attributable net losses continue, and how quickly the backlog converts into quarterly revenue.

07

Valuation

PER
—
PBR
1.3×
ROE
-19.5%
EPS
-₩632
BPS
₩2,951
Dividend per share
₩0

Because attributable net losses have continued over the last four quarters, a price-to-earnings ratio cannot be calculated on an earnings basis. The price-to-book ratio sits above 1 times book value, so the stock trades at a premium to net asset value.

Within equity of KRW 85.8 billion at the end of 2025, attributable equity was KRW 76.4 billion, and the debt-to-equity ratio rising to 88.6% means the capital structure change should be read alongside the multiples.

Over the longer run, operating margin recovered from 3.3% in 2023 to 7.9% in 2025, and attributable net income rose from KRW 3.74 billion in 2023 to KRW 7.13 billion in 2025, a clear direction of earnings recovery.

The dividend yield is low, and shareholder returns have so far appeared mainly as open-market share purchases by executives. Companies in the same IT and software classification differ in business model and revenue recognition, so direct comparisons are limited.

CRO revenue is recognized as projects progress after contract signing, so the timing with which the backlog converts into profit is the key variable for interpreting the multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Backlog and China-linked trial demand

According to media reports, backlog stood at approximately KRW 238.5 billion at the end of Q3 2026. In June 2026 the company said inquiries from Chinese biotech firms about Korean IND filings were rising quickly, and it described itself as practically the only domestic partner with a direct Tigermed channel.

A brokerage report cited in the same period expected bridge-trial demand from Chinese biotechs to contribute to growth from 2026.

Improving core-business trend

According to the company, standalone revenue in Q1 2026 rose 23.2% year on year to KRW 12.8 billion, and standalone operating profit rose 45.1% to KRW 1.3 billion. Media reports described cumulative revenue of KRW 54.9 billion for the first three quarters of 2026 as a record. The company said its CRO operating base remains solid.

Cash flow recovery and insider buying

Operating cash flow turned from negative to positive in 2025. A disclosure showed that CEO Yoo Jung-hee bought 26,400 shares on the open market in May 2026, raising his stake to 5.23%. Media reported that two senior executives also bought shares around the same time.

09

Bear factors

Four consecutive quarters of net losses

Attributable net losses have continued for four consecutive quarters from Q4 2025 through Q3 2026, totaling KRW 15.2 billion over the last four quarters. Q3 2026 operating profit of KRW 469 million fell 83.2% from a year earlier. Bears see the failure of higher revenue to translate into profit as the main problem.

Higher leverage and financing costs

The debt-to-equity ratio rose from 54.8% in 2024 to 88.6% in 2025. The company said financing costs, including interest on convertible bonds issued in 2025, weighed on consolidated results. Bears point to interest expense and valuation losses as factors widening earnings volatility.

Slow recovery in operating margin

Operating margin fell from 15.0% in 2022 to 3.3% in 2023 and recovered to 7.9% in 2025, still well below the 2022 level. After KRW 2.27 billion in Q2 2026, operating profit fell back to KRW 469 million in Q3. Bears argue that quarterly swings are too large to confirm a sustained recovery trend.

10

Risk factors

Pace of backlog conversion

Even a large backlog can see revenue recognition delayed if trials slip or clients change schedules. Clinical projects recognize revenue according to stage after contract signing, which creates quarter-to-quarter swings. Revenue of KRW 17.4 billion, KRW 20 billion and KRW 17.5 billion in Q1 to Q3 2026 illustrates this pattern.

Talent and labor cost pressure

Securing specialist staff and controlling labor costs affect project profitability, which the industry lists as a key risk. The company expanded its organization by hiring many staff from 2023, and it said efficiency later improved as new hires were trained and deployed. Operating margin fell to 3.3% in 2023 during that expansion, underscoring the importance of labor cost control.

Volatility from subsidiaries and investments

For Q1 2026, the company said consolidated results reflected subsidiary expansion costs, convertible bond interest and valuation losses from a decline in the share price of an investee. It also said a rise in investee value contributed to 2025 net income growth.

Because net income swings with investment valuations, the core business and non-recurring items need to be separated.

11

What to watch next

  1. Around February 2027 (typical timing, not confirmed)

    Preliminary Q4 and full-year 2026 results. The key checks are whether attributable net losses extend to a fifth consecutive quarter and whether the full-year operating margin exceeds the 7.9% of 2025.

  2. By March 31, 2027

    Filing of the 2026 annual report. The checks are backlog and revenue conversion over the full year, and how subsidiary costs and convertible bond interest were reflected in annual results.

  3. By May 15, 2027

    Filing of the Q1 2027 quarterly report. The checks are whether standalone core-business growth and consolidated operating profit move in the same direction, and whether the 88.6% debt-to-equity ratio persists.

12

Overall view

DreamCIS is a domestic CRO whose revenue grew from KRW 38.9 billion in 2022 to KRW 66.6 billion in 2025. Revenue rose three straight years from 2023 through 2025, and cumulative revenue of KRW 54.9 billion for the first three quarters of 2026 was reported as a record.

On the other side, operating margin of 7.9% in 2025 remained below the 15.0% of 2022, and attributable net losses have run for four consecutive quarters since Q4 2025. The debt-to-equity ratio rose to 88.6% in 2025, and the company cited financing costs such as convertible bond interest as a drag.

Growth arguments center on a backlog of approximately KRW 238.5 billion, demand from Chinese biotech firms for Korean trials, and the Tigermed network.

Attributable net losses totaling KRW 15.2 billion over the last four quarters and operating profit of KRW 469 million in Q3 2026 show that the profitability recovery is still in progress.

The next checkpoints are the operating margin and loss trend in the 2026 annual report, and core-business growth and financing costs in the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. wowtv.co.kr
  2. comp.fnguide.com
  3. jobkorea.co.kr
  4. thevc.kr
  5. news.dealsitetv.com
  6. medicopharma.co.kr
  7. news.nate.com
  8. news.dealsitetv.com
  9. stockhandbook.blog
  10. dreamcis.ninehire.site
  11. job-post.co.kr
  12. news.dealsitetv.com
  13. goinsider.kr
  14. news.dealsitetv.com
  15. digitaltoday.co.kr
  16. alicepapa.co.kr
  17. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis